---
title: "Huadong Medicine Advances Approval for Crohn's Disease Drug"
date: "2025-02-13 12:12:17"
summary: "Huadong Medicine subsidiary Sino-US Huadong received acceptance from China's medical products administrator for the market approval and supplemental application of ustekinumab injection for Crohn's disease. Ustekinumab, a biosimilar of Johnson &amp; Johnson's Stelara, blocks IL-12 and IL-23 pathways to treat autoimmune inflammation, according to a Thursday filing with the Shenzhen..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Huadong Medicine subsidiary Sino-US Huadong received acceptance from China's medical products administrator for the market approval and supplemental application of ustekinumab injection for Crohn's disease.

Ustekinumab, a biosimilar of Johnson & Johnson's Stelara, blocks IL-12 and IL-23 pathways to treat autoimmune inflammation, according to a Thursday filing with the Shenzhen bourse.

Shares of the pharmaceutical company rose less than 1% in recent trade.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250212:G2467143:0/)
